Health Canada has granted approval for StemCells to expand its Phase II clinical trial (Pathway Study) to evaluate the efficacy of company’s HuCNS-SC platform technology for chronic cervical spinal cord injury. The Phase II Pathway Study’s primary efficacy outcome is the change in motor strength of the…